| |
Value—x (%)
|
|---|
|
HNC (n = 422)
|
|---|
|
Age (y)
|
|
Mean
|
50
|
|
Range
|
26–73
|
|
Gender (n)
|
|
Male
|
381 (90.3 %)
|
|
Female
|
41 (9.7 %)
|
|
Tumor site
|
|
Larynx
|
48 (11.4 %)
|
|
Hypopharynx
|
68 (16.1 %)
|
|
Oropharynx
|
54 (12.8 %)
|
|
Oral cavity
|
102 (24.2 %)
|
|
Nasopharyngeal carcinoma
|
150 (35.5 %)
|
|
AJCC stage
|
|
I
|
0
|
|
II
|
34 (8.1 %)
|
|
III
|
95 (22.5 %)
|
|
IV
|
293 (69.4 %)
|
|
Cochlea mean dose
|
|
1–10
|
43 (10.2 %)
|
|
10–20
|
118 (28 %)
|
|
20–30
|
139 (32.9 %)
|
|
30–40
|
101 (23.9 %)
|
|
40–50
|
15 (3.6 %)
|
|
50–60
|
6 (1.4 %)
|
|
Tinnitus (grade 2+)
|
|
Yes
|
49 (11.6 %)
|
|
No
|
373 (88.4 %)
|
|
Cochlea mean dose Gy (range)
|
23.72 (1.73–58.83)
|
|
Without grade 2 + Tinnitus
|
22.44 (1.73–50.26)
|
|
With grade 2 + Tinnitus
|
33.46 (8.72–58.83)
|
|
Chemotherapy
| |
|
Yes
|
150 (35.5 %)
|
|
No
|
272 (64.5 %)
|
-
Abbreviation: AJCC American Joint Committee on Cancer, HNC head and neck cancer
